Platinum-based chemotherapy plus Imfinzi (durvalumab), Avastin (bevacizumab), and Lynparza (olaparib) confirmed a statistically vital and clinically significant enchancment in median progression-free survival versus chemotherapy and Avastin for the therapy of sufferers with newly recognized non-tBRCA–mutated ovarian most cancers, however didn’t present a major general survival profit, in accordance with closing general survival knowledge from the DUO-O trial offered through the
At a median follow-up of 56 months, findings from the third knowledge cutoff demonstrated that the median progression-free survival amongst sufferers with non-tBRCA–mutated illness within the intention-to-treat inhabitants who acquired chemotherapy with Imfinzi, Avastin, and Lynparza (arm 3; 378 sufferers) was 25.1 months in contrast with 19.3 months amongst those that acquired chemotherapy and Avastin (arm 1; 378 sufferers). Sufferers who acquired chemotherapy plus Avastin and Imfinzi (arm 2; 374 sufferers) had a median progression-free survival of 20.6 months, representing a profit versus arm 1.
The 24- and 48-month progression-free survival charges had been 53% and 30% in arm 3; these respective charges had been 39% and 22% in arm 2 and 33% and 16% in arm 1. Nevertheless, the median general survival in arm 3 was 50.5 months in contrast with 49.6 months in arm 1. Equally, the median general survival in arm 2 was 48.5 months, which didn’t signify a major profit versus arm 1. In arm 3, the 24- and 48-month general survival charges had been 83% and 53%; these respective charges had been 81% and 51% in arm 2 and 80% and 51% in arm 1.
“DUO-O met each main finish factors at knowledge cutoff 1, with a statistically vital and clinically significant progression-free survival enchancment for arm 3 versus arm 1 within the HRD-positive and intention-to-treat populations; this profit was maintained at knowledge cutoff 3 with an approximate median follow-up of 56 months,” Dr. Carol Aghajanian, the chief of the Gynecologic Medical Oncology Service and the Avon Chair in Gynecologic Oncology Analysis at Memorial Sloan Kettering Most cancers Middle in New York, New York, stated through the presentation. “At this closing general survival evaluation, the noticed progression-free survival advantages didn’t translate right into a statistically vital general survival enchancment.”
What was the Research Design of DUO-O?
DUO-O was a double-blind, multicenter examine that examined Imfinzi plus platinum-based chemotherapy and Avastin adopted by upkeep Imfinzi and Avastin or Imfinzi, Avastin, and Lynparza in sufferers with newly recognized superior ovarian most cancers. Eligible sufferers wanted to have FIGO stage 3 to 4 ovarian, main peritoneal, and/or fallopian-tube most cancers, in addition to be candidates for cytoreductive surgical procedure. Sufferers additionally wanted to be not less than 18 years previous, or not less than 20 years previous in the event that they enrolled in Japan, have an ECOG efficiency standing of 0 or 1, and have preserved organ and bone marrow perform. Eligible sufferers had been randomly assigned one-to-one-to-one to arms 1, 2, or 3.
Through the chemotherapy part, all sufferers acquired chemotherapy together with Avastin; these in arms 2 and three additionally acquired Imfinzi. Through the upkeep part, sufferers in arms 1, 2, and three acquired Avastin, Avastin plus Imfinzi, or Avastin plus Imfinzi and Lynparza, respectively. Upkeep remedy continued for as much as 2 years. The first finish level was investigator-assessed progression-free survival per RECIST 1.1 standards in arm 3 versus arm 1 in each the non-BRCA–mutated HRD-positive and intention-to-treat populations. Key secondary finish factors included investigator-assessed progression-free survival per RECIST 1.1 standards in arm 2 versus arm 1 within the non-BRCA–mutated intention-to-treat inhabitants, general survival, and security.
Extra Efficacy and Security Outcomes
Extra efficacy findings from DUO-O knowledge cutoff 3 revealed that the median progression-free survival amongst sufferers with non-tBRCA–mutated, HRD-positive illness was 45.1 months in arm 3 (140 sufferers) in contrast with 23.3 months in arm 1 (143 sufferers). In arm 2 (148 sufferers), the median progression-free survival was 25.6 months, representing a profit versus arm 1. In arm 3, the 24- and 48-month progression-free survival charges had been 73% and 47%; these respective charges had been 52% and 31% in arm 2 and 47% and 27% in arm 1.
By way of general survival amongst sufferers with non-tBRCA–mutated, HRD-positive illness, the median worth was not reached in arms 2 and three. In comparison with the 66.8-month median general survival in arm 1, sufferers in arm 3 skilled a 20% discount within the threat of demise and people in arm 2 had a 16% discount. In arm 3, the 24- and 48-month general survival charges had been 96% and 71%; these respective charges had been 92% and 71% in arm 2 and 89% and 68% in arm 1.
By way of security, any-grade unintended effects had been reported in arms 1 (99.2%), 2 (99.5%), and three (99.2%). Grade 3 (extreme) or increased unintended effects (62% versus 66% versus 73%), unintended effects resulting in demise (1.3% versus 2.4% versus 2.1%), severe unintended effects (35% versus 44% versus 40%), immune-mediated unintended effects (35% versus 57% versus 54%), unintended effects resulting in dose modification (72% versus 80% versus 86%), and unintended effects resulting in therapy discontinuation (21% versus 27% versus 35%) had been reported in all three arms. Unwanted effects of particular curiosity related to Lynparza that occurred in all three arms consisted of latest main malignancies (0.8% versus 0.3% versus 1.9%) and pneumonitis (0.8% versus 1.6% versus 1.9%).
“Security continues to be typically in step with the recognized profiles of every agent,” Aghajanian stated in her conclusion.
References
- “Imfinzi + paclitaxel/carboplatin + Avastin adopted by Imfinzi, Avastin + Lynparza upkeep in sufferers with newly recognized non-tBRCA–mutated superior ovarian most cancers: closing general survival from DUO-O” by Dr. Carol Aghajanian, et al., Offered on the 2025 ESMO Congress
- “Imfinzi therapy together with chemotherapy and Avastin, adopted by upkeep Imfinzi, Avastin, and Lynparza in superior ovarian most cancers sufferers (DUO-O)” by Dr. Carol Aghajanian, ClinicalTrials.gov
For extra information on most cancers updates, analysis and training,
